UBS Group
UNCY icon

UBS Group’s Unicycive Therapeutics UNCY Stock Holding History

UBS Group’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Sell
19,444
-461
-2% -$3.02K ﹤0.01% 6882
2025
Q4 		$115K Buy
19,905
+14,460
+266% +$77.2K ﹤0.01% 6841
2025
Q3 		$23.7K Buy
+5,445
New +$23.7K ﹤0.01% 8045
2025
Q2 		– Sell
-955
Closed -$5.49K – 10849
2025
Q1 		$5.49K Buy
+955
New +$5.82K ﹤0.01% 8987
2024
Q4 		– Hold
0
– – – 9864
2024
Q3 		– Hold
0
– – – 10088
2024
Q2 		– Sell
-439
Closed -$4.32K – 9440
2024
Q1 		$6.05K Buy
439
+421
+2,339% +$5.1K ﹤0.01% 7486
2023
Q4 		$153 Sell
18
-54
-75% -$353 ﹤0.01% 8862
2023
Q3 		$617 Sell
72
-45
-38% -$421 ﹤0.01% 8378
2023
Q2 		$1.5K Buy
+117
New +$1.83K ﹤0.01% 7906
2022
Q4 		– Sell
-119
Closed -$1K – 11160
2022
Q3 		$1K Sell
119
-330
-73% -$2.42K ﹤0.01% 10049
2022
Q2 		$4K Buy
+449
New +$4.29K ﹤0.01% 9141
2022
Q1 		– Sell
-527
Closed -$11K – 10931
2021
Q4 		$11K Buy
527
+465
+750% +$11.6K ﹤0.01% 8696
2021
Q3 		$2K Buy
+62
New +$1.78K ﹤0.01% 8998

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's UNCY Position: Q1 2026 in Review

UBS Group reduced its Unicycive Therapeutics (UNCY) stake by 2.3% in Q1 2026, selling an estimated $3.02K and leaving 19,444 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #6882.

UBS Group first reported a position in UNCY in Q3 2021 and has held it in 12 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • UBS Group held 19,444 shares of Unicycive Therapeutics worth $128K as of Q1 2026.
  • UBS Group sold 461 Unicycive Therapeutics shares in Q1 2026, an estimated $3.02K.
  • Unicycive Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6882 holding.
  • UBS Group first reported a position in Unicycive Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.